PRINCETON JUNCTION, N.J., July 10 Lutronic, Inc., one ofthe world's leading developers and manufacturers of aesthetic and medicallaser systems, announced today that it has received regulatory clearance fromthe U.S. FDA (Food and Drug Administration) for the eCO2 system.
Using the proprietary Controlled Chaos Technology (CCT), thisnext-generation fractional CO2 laser is designed to offer a safe andinnovative way to treat deep ablative indications such as resurfacing andcoagulation of soft tissue, textural irregularities, fine lines, pigmentedlesions, vascular dyschromia, and rhytides. The eCO2 has several features thatoffer customizable treatments that are easy to use and less painful to thepatients.
Dr. J. David Holcomb, immediate past president of the Florida Society ofFacial Plastic Surgeons, states that "the eCO2 is a familiar wavelength in anextremely elegant and versatile package, with the ability to performincisional surgery, traditional ablative resurfacing and ablativemicrofractional photothermolysis."
Of particular interest to users is the ability to combine two operationalmodes in one delivery system, which is important when deep penetration andgreater patient comfort is required. With both Static and Dynamic operationmodes, users have the capability to stamp up to a 14x14mm scan area as well asthe option to "feather" the treatment area to reduce the "checkerboard"appearance that is common with currently available fractional CO2 devices.
Further, at a 120 micron spot size, initial biopsy studies indicate thatthe laser can penetrate as deep as 2.4mm into the dermis. "We are seeinglong-lasting and consistent results after just one treatment with the eCO2system. Preliminary results show that patients may not need a follow-uptreatment," says Jhung Won Hwang, Ph.D., Sr. Director, Regulatory Affairs,Lutronic, Inc.
With several international and U.S. patents pending, the eCO2 has addedmultifunctional features, including an intuitive software that can selectbetween a random or sequential beam pattern, as well as a built-in skin sensortechnology that prevents the laser from firing unless the handpiece tip is incontact with the skin. A wide range of indications may be treated with its 3different treatment tip sizes, including a point beam tip for traditional CO2excision and vaporization of tissue-tags and pigmented lesions.
Dr. Holcomb continued, "With the safety of the eCO2 micro-fractionallaser, optimization of treatment protocols for off-face skin tightening andrejuvenation will be an area of intense interest."
Lutronic Corporation is a leading developer and manufacturer of medicallaser systems serving the dermatological and plastic surgery communities. Withdistribution in over 40 countries and over a decade of award-winningtechnology design that includes its Spectra line of products and itsunparalleled MOSAIC fractional systems, the company is committed to deliveringinnovative, highly effective, and painless laser solutions.
Lutronic continues to offer impressive customer service and support tophysicians and other qualified practitioners across the U.S. and globally. Tolearn more about the eCO2, please visit http://www.lutronic.com.
This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.Contact: Ken Reich Director, Marketing & Public Relations Lutronic, Inc. Phone: 609 275-1565 x302 or 888 588-7644 Fax: 609 275-3800 Email: firstname.lastname@example.org
SOURCE Lutronic, Inc.